In addition, since Golimumab which is one of other TNF inhibitors (36), and Anakinra and Canakinumab which are Interleukin (IL)-1 Inhibitors (37), are progressing to be used as new treatments for BD uveitis, it is expected further improving the visual prognosis of BD patients with uveitis. The gene discussed is TNF; the disease is uveitis.